Age is an important prognostic factor in COVID-19 patients treated with extracorporeal membrane oxygenation

Song-I Lee1^, Da Hyun Kang1^, Hong Joon Ahn2, Mi Joo Kim3, Man-Shik Shim4, Jeong Eun Lee1^  

1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University School of Medicine, Daejeon, Republic of Korea; 2Department of Emergency Medicine, College of Medicine, Chungnam National University School of Medicine, Daejeon, Republic of Korea; 3Division of Cardiology, Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Republic of Korea; 4Department of Cardiovascular Surgery, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Republic of Korea  

Correspondence to: Jeong Eun Lee. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chungnam National University School of Medicine, 282 Munhwa-ro, Jung-gu, Daejeon 35015, Republic of Korea. Email: vov-x@hanmail.net.

Submitted Apr 13, 2022. Accepted for publication Jun 24, 2022.  
doi: 10.21037/jtd-22-493  
View this article at: https://dx.doi.org/10.21037/jtd-22-493

Coronavirus disease 2019 (COVID-19) is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection affecting multiple organs and may progress to severe acute respiratory distress syndrome (ARDS). In South Korea, the shortage of intensive care unit (ICU) and application of extracorporeal membrane oxygenation (ECMO) are increasing due to the recent rapid increase in the number of critically ill patients with COVID-19. ECMO has been used in ARDS and reduces the 60-day mortality compared to that with conventional management (1). In the meta-analysis by Combes et al., 90-day mortality was significantly lower in the ECMO group than in the conventional management group [36% vs. 48%; relative risk 0.75; 95% confidence interval (CI): 0.6–0.94; P=0.013] (2). Mortality-related factors in ECMO include the age, malignancy, liver cirrhosis, ventilator setting [positive end-expiratory pressure (PEEP)], peak inspiratory pressure (PIP)], respiratory ECMO survival prediction (RESP) score, and predicting death due to severe ARDS on VV-ECMO (PRE SeverE) score (3,4).

Age is highly correlated with ECMO prognosis (3-5). The meta-analysis by Ramanathan et al., patients with COVID-19 who underwent ECMO showed that the duration, age, and body mass index were associated with mortality (6). Various scores have been used to predict the prognosis after ECMO initiation. However, despite the increasing application of ECMO due to COVID-19, whether the scoring system and age are helpful in predicting the prognosis of patients with COVID-19 who underwent ECMO is unclear. Therefore, we investigated the patients with COVID-19.

This is a single-center retrospective study on patients admitted at the 1200-bed tertiary academic hospital and ECMO referral center in South Korea. All data were obtained from electronic medical records. A total of 991 patients with COVID-19 hospitalized from January 2020 to December 2021 were included, excluding 952 patients (96.1%) who did not undergo ECMO. So, 39 patients (3.9%) who underwent ECMO were included in this study. The types of ECMO were venovenous in 31 patients (79.5%), venoarterial in five patients (12.8%), and venoarterial-venous in three patients (7.7%).

Reverse transcription-polymerase chain reaction analysis confirmed SARS-CoV-2 infection. ECMO was considered for patients with COVID-19 who worsened rapidly despite invasive mechanical ventilation (MV) and severe ARDS (PaO2/FiO2 ratio ≤100 mmHg), then their caregivers agreed to ECMO. The initiation of ECMO was decided

^ ORCID: Song-I Lee, 0000-0001-8372-4511; Da Hyun Kang, 0000-0002-3495-0931; Jeong Eun Lee, 0000-0001-6173-2748.
by consulting with the internal medicine department, which supervised the patients, and cardiovascular surgeon, perfusionist, and intensivist who specialize in ECMO. The ECMO insertion was performed by a cardiovascular surgeon and heparin was administered as an anticoagulant. The mortality risk factors were analyzed using the multivariate Cox proportional hazards model.

Among patients who underwent ECMO, 13 patients (33.3%) survived, and 26 patients (66.7%) did not. The non-survivors were older than the survivors [69.0 (65.3–73.5) vs. 49.0 (42.5–63.0) years, P<0.001] but there was no difference in the clinical frailty scale. Additionally, there was no difference for comorbidities; however, hypertension was more common in non-survivors (69.2% vs. 15.4%, P=0.002) (Table 1). There were no significant differences in the initial vital signs (systolic and diastolic blood pressure, heart rate, respiratory rate, and body temperature), laboratory data (white blood cell, hemoglobin, platelet, total bilirubin, albumin, blood urea nitrogen, creatinine, and C-reactive protein), and radiologic findings (unilateral, bilateral, and multifocal involvement of COVID-19).

There was no statistical difference in the use of remdesivir, antibiotics, and steroids for treatment; however, vasopressors (84.6% vs. 53.8%, P=0.048) and continuous renal replacement therapy (38.5% vs. 0%, P=0.010) were frequently used, and tocilizumab (7.7% vs. 38.5%, P=0.018) was less used in non-survivors. There was no difference in the application of PEEP, PIP, neuromuscular blockade, and prone position with MV treatment before ECMO (Table 1).

The patients’ scores before ECMO for Acute Physiology and Chronic Health Evaluation (APACHE) II score [27.0 (21.0–30.0) vs. 18.0 (16.5–21.5), P=0.012], PRESERVE score [5.0 (4.0–6.0) vs. 4.0 (1.0–5.0), P=0.023], and score by Roch et al. (7) [4.0 (2.0–4.0) vs. 3.0 (2.0–3.0), P=0.040] were higher in the non-survivor group than in the survivor

Table 1 Baseline characteristics, treatment and clinical outcomes of COVID-19 patients who underwent ECMO

| Variables                  | All patients (n=39) | Survivor (n=13) | Non-survivor (n=26) | P value |
|----------------------------|--------------------|-----------------|--------------------|---------|
| Age (years)                | 66.0 (55.0–72.0)   | 49.0 (42.5–63.0)| 69.0 (65.3–73.5)   | <0.001  |
| Male, n (%)                | 23 (59.0)          | 6 (46.2)        | 17 (65.4)          | 0.250   |
| Body mass index (kg/m²)    | 27.1 (24.4–29.8)   | 25.2 (23.4–28.6)| 27.7 (25.0–30.9)   | 0.267   |
| Clinical frailty scale     | 3.0 (2.0–3.0)      | 2.0 (1.5–3.0)   | 3.0 (2.0–3.0)      | 0.190   |
| Comorbidity, n (%)         |                    |                 |                    |         |
| Hypertension               | 20 (51.3)          | 2 (15.4)        | 18 (69.2)          | 0.002   |
| DM                         | 16 (41.0)          | 3 (23.1)        | 13 (50.0)          | 0.107   |
| COPD                       | 1 (2.6)            | 1 (7.7)         | 0 (0)              | 0.152   |
| Heart failure              | 4 (10.3)           | 0 (0)           | 4 (15.4)           | 0.135   |
| Liver cirrhosis            | 1 (2.6)            | 0 (0)           | 1 (3.8)            | 0.474   |
| Chronic kidney disease     | 1 (2.6)            | 0 (0)           | 1 (3.8)            | 0.474   |
| Malignancy                 | 4 (10.3)           | 1 (7.7)         | 3 (11.5)           | 0.709   |
| Treatment, n (%)           |                    |                 |                    |         |
| Remdesivir                 | 24 (61.5)          | 9 (69.2)        | 15 (57.7)          | 0.485   |
| Antibiotics                | 31 (79.5)          | 9 (69.2)        | 22 (84.6)          | 0.262   |
| Vasopressor                | 29 (74.4)          | 7 (53.8)        | 22 (84.6)          | 0.048   |
| CRRT                       | 10 (25.6)          | 0 (0)           | 10 (38.5)          | 0.010   |
| Steroid                    | 38 (97.4)          | 12 (92.3)       | 26 (100.0)         | 0.152   |
| Tocilizumab                | 7 (17.9)           | 5 (38.5)        | 2 (7.7)            | 0.018   |

Table 1 (continued)
The RESP score [1.5 (0.0–3.3) vs. 4.0 (3.0–7.0), P<0.001] was lower in the non-survivor group than in the survivor group. The sequential organ failure assessment (SOFA) score [12.0 (8.0–15.0) vs. 10.0 (8.5–11.0), P=0.118] showed no statistical difference between the two groups.

A comparison of the area under the curve for age and scoring system to predict the overall prognosis of patients with ECMO were as follows: age, 0.902 (95% CI: 0.805–0.999), APACHE II score, 0.741 (95% CI: 0.571–0.912), SOFA score, 0.651 (95% CI: 0.474–0.828), RESP score, 0.132 (95% CI: 0.020–0.244), PRESERVE score, 0.709 (95% CI: 0.541–0.877), and score by Roch et al., 0.691 (95% CI: 0.519–0.862). The optimal cutoff point for age was 65 years (sensitivity, 76.9%; specificity, 100%).

In this study, old age (≥65 years) was significantly associated with the prognosis of patients with COVID-19 who underwent ECMO and RESP score was associated with in-hospital mortality. Moreover, patients who underwent ECMO for COVID-19 have similar characteristics to those who underwent ECMO at ARDS. ECMO is usually performed in patients with severe ARDS, and prognosis is related to the experience of the ECMO center (8,9). Additionally, several scoring systems attempt to predict the patient’s prognosis and appropriately apply ECMO according to the patient’s financial burden and center’s workload. Previously, age has been shown to be an important prognostic factor in ECMO studies conducted in South Korea (5) and COVID-19 (6,10). However, whether the age and scoring system are better prognosis predictors for patients with COVID-19 who have received ECMO is unclear. Although this study was conducted in a limited number of patients and single center, it revealed that age is an important factor related to the prognosis of ECMO. We recommend determining ECMO treatment by considering age with the RESP score in situations of ICU shortage and lack of critical care resources.

### Acknowledgments

We would like to thank Editage (www.editage.co.kr) for English language editing.

**Funding:** None.
Footnote

Provenance and Peer Review: This article was a standard submission to the journal. The article has undergone external peer review.

Peer Review File: Available at https://jtd.amegroups.com/article/view/10.21037/jtd-22-493/prf

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-22-493/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Munshi L, Walkey A, Goligher E, et al. Venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a systematic review and meta-analysis. Lancet Respir Med 2019;7:163-72.
2. Combes A, Peek GJ, Hajage D, et al. ECMO for severe ARDS: systematic review and individual patient data meta-analysis. Intensive Care Med 2020;46:2048-57.
3. Schmidt M, Bailey M, Sheldrake J, et al. Predicting survival after extracorporeal membrane oxygenation for severe acute respiratory failure. The Respiratory Extracorporeal Membrane Oxygenation Survival Prediction (RESP) score. Am J Respir Crit Care Med 2014;189:1374-82.
4. Schmidt M, Zogheib E, Rozé H, et al. The PRESERVE mortality risk score and analysis of long-term outcomes after extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. Intensive Care Med 2013;39:1704-13.
5. Baek MS, Chung CR, Kim HJ, et al. Age is major factor for predicting survival in patients with acute respiratory failure on extracorporeal membrane oxygenation: a Korean multicenter study. J Thorac Dis 2018;10:1406-17.
6. Ramanathan K, Shekar K, Ling RR, et al. Extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis. Crit Care 2021;25:211.
7. Roch A, Hraiech S, Masson E, et al. Outcome of acute respiratory distress syndrome patients treated with extracorporeal membrane oxygenation and brought to a referral center. Intensive Care Med 2014;40:74-83.
8. Lebreton G, Schmidt M, Ponnaiah M, et al. Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: a multicentre cohort study. Lancet Respir Med 2021;9:851-62.
9. Tabatabai A, Ghneim MH, Kaczorowski DJ, et al. Mortality Risk Assessment in COVID-19 Venovenous Extracorporeal Membrane Oxygenation. Ann Thorac Surg 2021;112:1983-9.
10. Barbaro RP, MacLaren G, Boonstra PS, et al. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. Lancet 2020;396:1071-8.

Cite this article as: Lee SI, Kang DH, Ahn HJ, Kim MJ, Shim MS, Lee JE. Age is an important prognostic factor in COVID-19 patients treated with extracorporeal membrane oxygenation. J Thorac Dis 2022;14(8):3094-3097. doi: 10.21037/jtd-22-493